For the quarter ending 2025-09-30, CLNNW had $640K increase in cash & cash equivalents over the period. -$4,003K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,777 | -8,170 |
| Depreciation | 365 | 770 |
| Non-cash lease expense | 148 | 270 |
| Issuance of common stock as payment of outstanding indebtedness | 0 | -8 |
| Change in fair value of common stock warrant liabilities | 1,728 | -1,995 |
| Change in fair value of derivative liabilities | -797 | 708 |
| Change in fair value of clene nanomedicine contingent earn-out liability | 0 | 0 |
| Change in fair value of initial stockholders contingent earn-out liability | 0 | 0 |
| Stock-based compensation expense | 1,703 | 3,314 |
| Accretion of debt discount | 252 | 488 |
| Non-cash interest income on marketable securities | 0 | 0 |
| Non-cash interest expense on notes payable | -216 | -24 |
| Accounts receivable | 0 | -64 |
| Inventory | -18 | 11 |
| Prepaid expenses and other current assets | 66 | 751 |
| Accounts payable | 541 | -412 |
| Accrued liabilities | -465 | -2,307 |
| Operating lease obligations | -452 | -339 |
| Net cash used in operating activities | -3,992 | -9,755 |
| Purchases of marketable securities | 0 | 0 |
| Proceeds from maturities of marketable securities | 0 | 0 |
| Purchases of property and equipment | 11 | 0 |
| Net cash provided by (used in) investing activities | -11 | 0 |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from issuance of common stock, net of offering costs | 3,266 | 4,977 |
| Proceeds from share subscriptions payable | 0 | - |
| Proceeds from the issuance of debt and derivative liabilities | 1,500 | - |
| Payments of notes payable | 124 | 171 |
| Payments of finance lease obligations | 0 | 0 |
| Net cash provided by (used in) financing activities | 4,642 | 4,806 |
| Effect of foreign exchange rate changes on cash and restricted cash | 1 | 79 |
| Net decrease in cash, cash equivalents and restricted cash | 640 | -4,870 |
| Cash and cash equivalents at beginning of period | 12,213 | - |
| Cash and cash equivalents at end of period | 7,983 | - |
Clene Inc. (CLNNW)
Clene Inc. (CLNNW)